Turner Syndrome

Findings in pediatric in children reported from University of North Carolina, Division of Pediatric Endocrinology

Turner Syndrome Library Library Home This article was published in Biotech Business Week, which you can subscribe to online.

"Secondary objectives were to identify factors associated with treatment response, to determine whether outcome could be predicted by a regression model using these factors, and to assess the safety of GH treatment in this young cohort. This study was a prospective, randomized, controlled, open-label, multicenter clinical trial (Toddler Turner Study, August 1999 to August 2003). The study was conducted at 11 U.S. pediatric endocrine centers. Eighty-eight girls with TS, aged 9 months to 4 yr, were enrolled. comprised recombinant GH (50 mug/kg.d; n=45) or no treatment (n=43) for 2 yr. The main outcome measure was baseline-to-2-yr change in height SDS. Short stature was evident at baseline (mean length/height SDS=-1.6 ±1.0 at mean age 24.0 ±12.1 months). Mean height SDS increased in the GH group from -1.4 ±1.0 to -0.3 ±1.1 (1.1 SDS gain), whereas it decreased in the control group from -1.8 ±1.1 to -2.2 ±1.2 (0.5 SDS decline), resulting in a 2-yr between-group difference of 1.6 ±0.6 SDS (p <0.0001). The baseline variable that correlated most strongly with 2-yr height gain was the difference between mid-parental height SDS and subjects' height SDS (r=0.32; p=0.04). Although attained height SDS at 2 yr could be predicted with good accuracy using baseline variables alone (R(2)=0.81; p<0.0001), prediction of 2-yr change in height SDS required inclusion of initial treatment response data (4-month or 1-yr height velocity) in the model (R(2)=0.54; p<0.0001)," wrote M.L. Davenport and colleagues, University of North Carolina, Division of Pediatric Endocrinology.

The researchers concluded: "No new or unexpected safety signals associated with GH treatment were detected. Early GH treatment can correct growth failure and normalize height in infants and toddlers with TS."

Davenport and colleagues published their study in the Journal of Clinical Endocrinology & Metabolism (Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. Journal of Clinical Endocrinology & Metabolism, 2007;92(9):3406-16).

For additional information, contact M.L. Davenport, University of North Carolina, Division of Pediatric Endocrinology, CB 7039, 3341 Medical Biomolecular Research Building, Chapel Hill, North Carolina 27599-7039 USA..

Publisher contact information for the Journal of Clinical Endocrinology & Metabolism is: Endocrine Society, 8401 Connecticut Avenue, Suite 900, Chevy Chase, MD 20815-5817, USA.

Keywords: United States, Chapel Hill, Life Sciences, Pediatric, Syndrome, Clinical Trial Research, Hormones, Clinical Endocrinology, Metabolism.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.